Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Buprenorphine in Sickle Cell Disease
NCT03492099Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Aug 2018
- Primary completion
- Sep 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of buprenorphine in sickle cell disease (SCD), sponsored by Johns Hopkins University. Primary endpoint: Number of Subjects Who Require Hospitalization Within 72 Hours Post Conversion. Started Aug 2018; status: completed.
02
Drugs
buprenorphine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03492099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492099.